IPSEN, OOO
- Country
- 🇷🇺Russia
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 108
- Registration Number
- NCT00690898
- Locations
- 🇨🇿
Všeobecná fakultní nemocnice, Karlova Univerzita, Praha, Czechia
🇫🇮The Turku University Central Hospital, Turku, Finland
🇫🇷Hopital De Bois Guillaume, Bois-Guillaume, France
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
- Conditions
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 260
- Registration Number
- NCT00686348
- Locations
- 🇺🇸
Ipsen, Basking Ridge, New Jersey, United States
Somatuline Autogel Preference and Health Economy Study
- Conditions
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 26
- Registration Number
- NCT00681187
- Locations
- 🇳🇴
Haukeland University Hospital / Kreftafd, Bergen, Norway
🇳🇴University Hospital North-Norway / GastroLab, Tromsø, Norway
🇳🇴S:t Olavs Hospital / Medisinsk Afd, Trondheim, Norway
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
- Conditions
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 81
- Registration Number
- NCT00578097
- Locations
- 🇧🇪
UZ Gasthuisberg, Leuven, Belgium
🇨🇿Urologická klinika, Olomouc, Czechia
🇫🇷Hôpital Michallon - CHU de Grenoble, Grenoble Cedex, France
Long-Term Treatment With rhIGF-1 in GHIS
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 92
- Registration Number
- NCT00571727
- Locations
- 🇺🇸
Ipsen, Brisbane, California, United States
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 106
- Registration Number
- NCT00572156
- Locations
- 🇺🇸
Ipsen, Brisbane, California, United States
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
- Conditions
- Interventions
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 37
- Registration Number
- NCT00564850
- Locations
- 🇫🇷
Hôpital Hotel-Dieu (CHU), Angers, France
🇫🇷Hôpital Saint-Jacques, Besancon, France
🇫🇷Medical Centre, Bordeaux, France
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Ipsen
- Registration Number
- NCT00517491
- Locations
- 🇲🇽
Centro Médico Nacional Siglo XXI, IMSS, Mexico City, Mexico
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
- Conditions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 55
- Registration Number
- NCT00500227
- Locations
- 🇪🇸
Hospital Prínceps d'Espanya, Barcelona, Spain
🇪🇸Hospital General de la Vall d´Hebron, Barcelona, Spain
🇪🇸Hospital "Mútua de Terrassa", Barcelona, Spain
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
- Conditions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 63
- Registration Number
- NCT00499993
- Locations
- 🇮🇹
Ospedale Maggiore, Bologna, Italy
🇮🇹Università deglis Studi di Cagliari, Cagliari, Italy
🇮🇹Azienda Ospedaliera "V. Cervello", Palermo, Italy